Pharmacologic and clinical evaluation of posaconazole.

Authors

Jason N. Moore, Thomas Jefferson UniversityFollow
Jason R. Healy, Thomas Jefferson UniversityFollow
Walter K. Kraft, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

5-1-2016

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Expert Review of Clinical Pharmacology

Volume 8, Issue 3, May 2015, Pages 321-334.

The published version is available at DOI: 10.1586/17512433.2015.1034689. Copyright © Informa

Abstract

Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral tablet and intravenous solution formulations provide an attractive treatment option by reducing interpatient variability and providing flexibility in critically ill patients. On the basis of clinical experience and further clinical studies, posaconazole was found to be a valuable pharmaceutical agent for the treatment of life-threatening fungal infections. This review will examine the development history of posaconazole and highlight the most recent advances.

Recommended Citation

Moore, Jason N.; Healy, Jason R.; and Kraft, Walter K., "Pharmacologic and clinical evaluation of posaconazole." (2016). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 60.
https://jdc.jefferson.edu/petfp/60

PubMed ID

25916666